Medicine for treating prostate hyperplasia

Abstract

The invention relates to a medicine for treating prostate hyperplasia, which is prepared from the following raw materials according to parts by weight: 10-20 parts of mulberry leaf, 10-20 parts of ginkgo leaf, 3-5 parts of gynostemma pentaphylla, 10-12 parts of wheat bran, 4-6 parts of evodia rutaecarpa, 6-8 parts of fructus citri sarcodactylis, 6-8 parts of herba eupatorii, 10-14 parts of wrinkled gianthyssop, 6-8 parts of officinal magnolia, 5-7 parts of inula flower, 4-6 parts of snakegourd fruit, 10-12 parts of red ginseng, 6-10 parts of radix salviae miltiorrhizae, 8-10 parts of red peony root, 8-10 parts of rhizoma ligustici wallichii, 12-14 parts of radix notoginseng, 8-10 parts of rhizoma corydalis, 10-14 parts of ophiopogon root and 8-10 parts of rosa banksiae. The invention has the advantages of small toxic or side effect, convenient taking, easy absorption, quick acting, good curative effect, low price and quick function and conforms to the national relevant standard by inspection. The clinical application observation confirms that the acting is quick. Compared with the traditional medicines, such as Qianliekang and the like, the traditional Chinese medicine preparation for treating the prostate hyperplasia disease has the characteristics of long acting, quick acting and high efficiency.

Description

(1) Technical field [0001] The invention relates to a medicine for treating benign prostatic hyperplasia. (2) Background technology [0002] Prostatic hyperplasia is a frequently-occurring disease that mostly occurs in middle-aged and elderly comrades. It is manifested as frequent urination, fine urinary stream or difficulty in urinating, and even urinary retention, which brings great pain to patients. At present, most of the drugs for the treatment of benign prostatic hyperplasia are oral drugs, but the course of treatment is long, easy to relapse, curative effect is limited, side effects are large, and the symptoms cannot be improved comprehensively. Surgical therapy is prone to serious complications. Old and frail patients with benign prostatic hyperplasia have more postoperative morbidity and complications. Therefore, there is still a lack of an effective comprehensive treatment drug for benign prostatic hyperplasia. (3) Contents of the invention [0003] In order to...

AI Technical Summary

Problems solved by technology

At present, most of the drugs for the treatment of benign prostatic hyperplasia are mainly oral drugs, but the course of treatment is long, easy to relapse, limited curative effect, side effects are large, and cannot comprehensively improve symptoms

Surgical therapy is prone to serious complications. Old and frail patients with benign prostatic hyperplasia have more postoperative morbidity and complications

Therefore, there is still a lack of an effective comprehensive treatment drug for benign prostatic hyperplasia.